Close

Prof Pontiano Kaleebu

Professor of Immunovirology*

United Kingdom

Affiliations

MRC/UVRI and LSHTM Uganda Research Unit

Selected Publications

Emerging threat of artemisinin partial resistance markers (pfk13 mutations) in Plasmodium falciparum parasite populations in multiple geographical locations in high transmission regions of Uganda.
Agaba, BB; Travis, J; Smith, D; Rugera, SP; Zalwango, MG; Opigo, J; Katureebe, C; Mpirirwe, R; Bakary, D; ANTONIO, M; Khalid, B; Ngonzi, J; Kamya, MR; KALEEBU, P; PIOT, P; Cheng, Q;
2024
Malaria journal
The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents (POPVAC C): an open-label, randomised controlled trial.
Nassuuna, J; ZIRIMENYA, L; NKURUNUNGI, G; Natukunda, A; Zziwa, C; Ninsiima, C; Apule, B; Onen, C; Amongi, S; Serubanja, J; Tumwesige, P; Nsubuga, D; Amongin, R; Van Dam, GJ; Corstjens, PL A M; Kayiwa, J; Kabagenyi, J; Cose, S; WAJJA, A; KALEEBU, P; WEBB, EL; ELLIOTT, AM; POPVAC trial team,;
2024
The Lancet Global health
The effect of intensive praziquantel administration on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands (POPVAC A): an open-label, randomised controlled trial.
NKURUNUNGI, G; Nassuuna, J; Natukunda, A; ZIRIMENYA, L; Walusimbi, B; Zziwa, C; Ninsiima, C; Kabagenyi, J; Kabuubi, PN; Van Dam, GJ; Corstjens, PL A M; Kayiwa, J; Kizza, M; Mutebe, A; Nakazibwe, E; Akello, FA; Sewankambo, M; Kiwanuka, S; Cose, S; WAJJA, A; KALEEBU, P; WEBB, EL; ELLIOTT, AM; POPVAC trial team,;
2024
The Lancet. Global health
Crimean-Congo hemorrhagic fever cases diagnosed during an outbreak of Sudan virus disease in Uganda, 2022-23.
Balinandi, S; Mulei, S; Whitmer, S; Nyakarahuka, L; Cossaboom, CM; Shedroff, E; Morales-Betoulle, M; Krapiunaya, I; Tumusiime, A; Kyondo, J; Baluku, J; Namanya, D; Torach, CR; Mutesi, J; Kiconco, J; Pimundu, G; Muyigi, T; Rowland, J; Nsawotebba, A; Ssewanyana, I; Muwanguzi, D; Kadobera, D; Harris, JR; Ario, AR; Atek, K; ... Klena, JD.
2024
PLoS neglected tropical diseases
Schistosome and malaria exposure and urban-rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials.
Natukunda, A; NKURUNUNGI, G; ZIRIMENYA, L; Nassuuna, J; Zziwa, C; Ninsiima, C; Tumusiime, J; Nyanzi, R; Namutebi, M; Kiwudhu, F; Van Dam, GJ; Corstjens, PL A M; Kizindo, R; Nkangi, R; Kabagenyi, J; Nassanga, B; Cose, S; WAJJA, A; KALEEBU, P; ELLIOTT, AM; WEBB, EL; POPVAC trial team,;
2024
The Lancet Global Health
The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial.
ZIRIMENYA, L; Natukunda, A; Nassuuna, J; NKURUNUNGI, G; Zziwa, C; Ninsiima, C; Kukundakwe, C; Nankabirwa, CM; Katushabe, C; Namusobya, LK; Oduru, G; Kabami, G; Kabali, J; Kayiwa, J; Kabagenyi, J; Van Dam, GJ; Corstjens, PL A M; Cose, S; WAJJA, A; Staedke, SG; KALEEBU, P; ELLIOTT, AM; WEBB, EL; POPVAC trial team,;
2024
The Lancet Global health
A Lipid Nanoparticle-Formulated Self-Amplifying RNA Rift Valley Fever Vaccine Induces a Robust Humoral Immune Response in Mice.
Kitandwe, PK; Rogers, P; Hu, K; Nayebare, O; Blakney, AK; McKay, PF; KALEEBU, P; Shattock, RJ;
2024
Vaccines
Next-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile among Individuals on First-Line ART.
Nannyonjo, M; Omooja, J; Bugembe, DL; BBOSA, N; Lunkuse, S; Nabirye, SE; Nassolo, F; Namagembe, H; ABAASA, A; Kazibwe, A; KALEEBU, P; Ssemwanga, D;
2024
Viruses
The 2023 South Sudanese outbreak of Hepatitis E emphasizes ongoing circulation of genotype 1 in North, Central, and East Africa.
Orf, GS; BBOSA, N; Berg, MG; Downing, R; Weiss, SL; Ssemwanga, D; Ssekagiri, A; Ashraf, S; Da Silva Filipe, A; Kiiza, R; Buule, J; Namagembe, HS; Nabirye, SE; Kayiwa, J; Deng, LL; Wani, G; Maror, JA; Baguma, A; Mogga, JJ H; Kamili, S; THOMSON, EC; KALEEBU, P; Cloherty, GA;
2024
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
Serwanga, J; Oluka, GK; Baine, C; Ankunda, V; Sembera, J; Kato, L; Katende, JS; Odoch, G; Auma, BO; Gombe, B; COVID-19 Immunoprofiling Team,; Musenero, M; KALEEBU, P;
2024
PloS one
See more information